Document is current
Any future updates will be listed below
-
Authors
Jiang, Haiping
Yu, Xiongfei
Li, Ning
Kong, Mei
Ma, Zhimin
Zhou, Donghui
Wang, Weibin
Wang, Haohao
Wang, Haiyong
He, Kuifeng
Li, Zhongqi
Lu, Yimin
Zhang, Jing
Zhao, Kui
Zhang, Yafei
Xu, Nong
Li, Ziran
Liu, Ying
Wang, Yan
Wang, Yisen
Teng, Lisong
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04065282 at ClinicalTrials.govnct03221426 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
https://doi.org/10.1136/jitc-2021-003635
nct04592913 at ClinicalTrials.govDocuments that mention this clinical trial
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
https://doi.org/10.1136/jitc-2019-000404
Neoadjuvant/adjuvant pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585.
https://doi.org/10.1200/jco.2024.42.16_suppl.4073
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
https://doi.org/10.1136/jitc-2021-003635
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study
https://doi.org/10.1200/jco-25-00486
Pembrolizumab plus FLOT vs FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: Interim analysis of the phase 3 KEYNOTE-585 study.
https://doi.org/10.1200/jco.2024.42.3_suppl.247
nct04139135 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
https://doi.org/10.1136/jitc-2021-003635
Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study.
https://doi.org/10.1200/jco.2024.42.3_suppl.lba246
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658
Documents that mention this clinical trial
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
https://doi.org/10.1136/jitc-2021-003635
-
Funding
Funding for this research was provided by:
National Health and Family Planning Commission Research Fund & Zhejiang Provincial Medical and Health Major Science and Technology Plan Project (KWJ-ZJ-2108)
Public Welfare Technology Application Research Project of Zhejiang Province (LGF20E030004)
Innovent Biologics, Inc.
- License Information
